Navigation Links
Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Date:6/11/2009

About Dimebon

Dimebon is an investigational compound currently in Phase 3 development for the treatment of Alzheimer's disease and in clinical development for Huntington disease. In preclinical models of Alzheimer's disease and Huntington disease explored thus far, dimebon has been shown to inhibit brain cell death, potentially by stabilizing and improving mitochondrial function in a way that prevents neuron death and dysfunction. The dimebon mechanism is thought to be distinct from that of currently available Alzheimer's disease medications.

In addition to CONNECTION, dimebon is being studied in the 12-month Phase 3 CONCERT trial, which is evaluating the efficacy of dimebon when added to ongoing treatment with donepezil (Aricept(R)) in patients with mild-to-moderate Alzheimer's disease, and in a Phase 3 safety study. Two Phase 3 studies in moderate-to-severe Alzheimer's disease are also planned to start this year.

In Huntington disease, a Phase 2 study has been completed. Medivation and Pfizer expect to initiate a Phase 3 trial this year to evaluate the potential benefits of dimebon on cognition in patients with Huntington disease.

About Alzheimer's Disease

Alzheimer's disease is a progressive degenerative brain disorder that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities. As the disease progresses, patients may experience changes in personality and behavior, such as anxiety, suspiciousness or agitation, as well as delusions or hallucinations.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Announces Pricing of Public Offering
2. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
3. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
4. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
5. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Presents New Data on Dimebons Novel Mechanism of Action
7. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
8. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
9. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
10. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
11. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... --  BioTE Medical , a leading provider of ... today announced the addition of Dr. Neal ... is joining the BioTE Medical Advisory Board as ... was residency trained in Family Medicine and Emergency ... emergency physician still practicing at a large metropolitan ...
(Date:7/22/2014)... The DNA Spectrum Ancestry Map provides ... history, migration, and culture. , Throughout his childhood ... stories stemming from Europe. His father passionately referred to ... 8mm home movies painted an elaborate picture of an ... ordered a test from DNA Spectrum to expand upon ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 /PRNewswire/ ... filiale di BGI, la maggiore organizzazione di genomica del ... servizio di sequenziamento dell,intero esoma umano con base la ... Complete Genomics, molto apprezzata nel settore per essere ... il 99.999% di precisione e una rilevazione altamente sensibile ...
(Date:7/22/2014)... 22, 2014  Semler Scientific, Inc. (Nasdaq: ... assessment company that develops patented products that assist ... diseases, today announced that it will report second ... U.S. financial markets on July 25, 2014. Doug Murphy-Chutorian, M.D., ... conference call at 11 a.m. EDT, July 25, 2014. ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2
... BEDMINSTER, N.J., Nov. 8, 2010 Omthera ... company, today announced the initiation of a ... evaluate the bioavailability of Epanova™, Omthera,s lead ... triglycerides, in comparison to Lovaza®, the leading ...
... (Nasdaq: TPCG ) today announced that it has commenced ... of its common stock at a purchase price of not less ... purchase shares having an aggregate purchase price of no more than ... stockholders may tender all or a portion of their shares (1) ...
... at the Kavli Institute of NanoScience, has been awarded ... his research into improved microscopic technologies. The technologies enable ... semiconductor nanowires, all the way down to atomic level. ... are made visible in this way can be measured ...
Cached Biology Technology:Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 3TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 2TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 3TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 4ERC advanced grant for Professor Zandbergen's 'nanolaboratory' 2
(Date:7/22/2014)... Arlington computer science and engineering professor with an expertise ... National Science Foundation grant worth more than $600,000 to ... fruit fly., Heng Huang, an associate professor, will lead ... UT Arlington Computer Science and Engineering department. Scientists are ... a large number of genes involved in fruit fly ...
(Date:7/22/2014)... the average steak, but it seems to help wood ... winter cold. , "Alaska wood frogs spend more time ... your freezer and the frog comes back to life ... said Don Larson, University of Alaska Fairbanks graduate student ... freeze tolerance in Alaska wood frogs is more extreme ...
(Date:7/22/2014)... the USC Schaeffer Center for Health Policy and ... drugs with increased incarceration rates for schizophrenic individuals. ... whether cutbacks in mental health actually save money, ... Some health plans require an extra approval step ... patients. This step called prior authorization ...
Breaking Biology News(10 mins):UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2
... Sept. 26 2007 -- Consuming large amounts of caffeine ... painkillers in the United States, could potentially cause liver ... the Oct. 15 print issue of ACS Chemical Research ... occur not only from drinking caffeinated beverages while taking ...
... the magnetic reference direction, have recently been found in ... 2004). Furthermore, studies investigating what parts of a migratory ... magnetic compass showed that the cryptochrome-containing neurons in the ... al., PNAS, 2005; Liedvogel et al., EJN, 2007) are ...
... 25, 2007) Your body goes to a lot of ... brains neural pathways are impaired through injury, age or illness, ... to perform the constant yet delicate balancing act required for ... robots that can balance like humans, researchers at Georgia Tech ...
Cached Biology News:Mixing large doses of both acetaminophen painkiller and caffeine may increase risk of liver damage 2Simulation reveals how body repairs balance after damage 2Simulation reveals how body repairs balance after damage 3